Sweat gland disorder

Summary

Sweat gland disorder (MONDO:0006615) is a disease (an umbrella term covering 6 Mondo subtypes) with 2 GWAS associations across 8 studies and 5 clinical trials. Top therapeutic interventions include oxybutynin and glycopyrronium. A subtype of skin disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Umbrella term: 6 Mondo subtypes
• GWAS associations: 2
• Clinical trials: 5

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	sweat gland disorder
Mondo ID	MONDO:0006615
MeSH	D013543
DOID	DOID:1383
SNOMED CT	88232005
UMLS	C0262643
MedGen	892310
Anatomy (UBERON)	UBERON:0001820
Is cancer (heuristic)	no

Also known as: disease of sweat gland · disease or disorder of sweat gland · disorder of sweat gland · sweat gland disease · sweat gland disease or disorder

Data availability: 2 GWAS associations (8 studies).

Disease family

This is a subtype of skin disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › integumentary system disorder › skin disorder › sweat gland disorder

Related subtypes (71): dermatitis, cutaneous mucinosis, skin neoplasm, pyoderma, chronic ulcer of skin, systemic sclerosis, sunburn, severe cutaneous adverse reaction, paronychia, Achenbach syndrome, erythema multiforme, erythematosquamous dermatosis, exanthem, facial dermatosis, hand dermatosis, keratosis, leg dermatosis, lichen disease, lipodystrophy, mongolian spot, reactive cutaneous fibrous lesion, rosacea, scalp dermatosis, sebaceous gland disorder, skin atrophy, skin sarcoidosis, vesiculobullous skin disease, hyperglobulinemic purpura, ainhum, cheilitis glandularis, erythema palmare hereditarium, multiple benign circumferential skin creases on limbs, actinic prurigo, congenital lethal erythroderma, Parana hard-skin syndrome, Bazex-Dupre-Christol syndrome, nephrogenic systemic fibrosis, erosive pustular dermatosis of the scalp, pseudoxanthoma elasticum-like papillary dermal elastolysis, toxic dermatosis, oral erosive lichen, chronic actinic dermatitis, Jessner lymphocytic infiltration of the skin, acquired kinky hair syndrome, primary cutaneous plasmacytosis, cutaneous pseudolymphoma, corticosteroid-sensitive aseptic abscess syndrome, interstitial granulomatous dermatitis with arthritis, epidermal disease, skin pigmentation disorder, skin vascular disease, Wells syndrome, solar urticaria, pellagra, hereditary epidermal appendage anomaly, keratosis pilaris, dermis disorder, aquagenic pruritus, Boudhina Yedes Khiari syndrome, non-neoplastic nevus, cutaneous sclerosis, pityriasis rotunda, hematohidrosis, skin disorder caused by infection, livedoid vasculopathy, prurigo nodularis, granuloma faciale, sclerema neonatorum, hereditary skin disorder, hand-foot syndrome, Nicolau syndrome

Subtypes (6): sweat gland neoplasm, anhidrosis, dyshidrosis, Fox-Fordyce disease, miliaria, apocrine sweat gland disorder

Genetics & variants

GWAS landscape

2 GWAS associations across 8 studies. Top hits map to 1 distinct genes (as reported by GWAS).

Top associations by p-value

rsID	p-value	Gene	Risk allele	Odds ratio
rs558850072	1e-11	TCERG1L	G	2.13
rs79326172	8e-09	LINC02041 - SST	?

Top studies (by case count)

Study	Lead author	Year	Cases	Controls	Title
GCST90478830	Verma A	2024	3,232	441,540	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90478829	Verma A	2024	1,865	117,522	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90480480	Verma A	2024	1,865	117,522	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90473967	UK Biobank Whole-Genome Sequencing Consortium	2025	1,061	457,379	Whole-genome sequencing of 490,640 UK Biobank participants.
GCST90436628	Zhou W	2018	817	399,255	Efficiently controlling for case-control imbalance and sample relatedness in large-scale genetic association studies.
GCST90478828	Verma A	2024	584	58,405	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90651439	Liu TY	2025	494	227,516	Diversity and longitudinal records: Genetic architecture of disease associations and polygenic risk in the Taiwanese Han population.
GCST90727051	Kim HI	2026	289	43,737	Exome sequencing and analysis of 44,028 British South Asians enriched for high autozygosity.

Variant details and genetic-evidence tiers

Tier distribution (top 50 variants)

Tier	Variants
Tier 1: coding	0
Tier 2: splice/UTR	0
Tier 3: regulatory	0
Tier 4: intronic/intergenic	2

MAF distribution

Bucket	Variants
common (>=0.05)	0
low_freq (0.01-0.05)	0
rare (<0.01)	1
unknown	1

Functional consequences

Consequence	Count
intron_variant	2

Top variants

rsID	Chr	Pos	Alleles	MAF	Consequence	Gene	p-value	Tier
rs558850072	10	131208509	G>A	0	intron_variant	TCERG1L	1e-11	Tier 4: intronic/intergenic
rs79326172	3	187512498	A>G		intron_variant	LINC02041 - SST	8e-09	Tier 4: intronic/intergenic

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 5.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2	3
PHASE1	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05102396	PHASE2	RECRUITING	Topical Oxybutynin for Treatment of Hyperidrosis: Local or Systemic Effect?
NCT03426085	PHASE2	UNKNOWN	The Effects of Liraglutide on Sudomotor Function and Inflammation in Type 2 Diabetes
NCT04906655	PHASE2	COMPLETED	An Open Label Study for Palmar Hyperhydrosis
NCT02304562	PHASE1	UNKNOWN	Umbilical Cord Blood-derived Mesenchymal Stem Cells in Regeneration of Sweat Glands and Body Repair
NCT01539460	Not specified	UNKNOWN	A Minimally Invasive Surgery for Axillary Osmidrosis: Combined Liposuction With Subcutaneous Pruning

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
OXYBUTYNIN	4	3
GLYCOPYRRONIUM	4	1